Differential RNA Transcriptome in Ustekinumab Responders vs Non-Responders

J Drugs Dermatol. 2023 Feb 1;22(2):219-222.

Abstract

Despite numerous available psoriasis treatments, no "one size fits all" regimen provides complete disease control without side effects, logistical obstacles, and/or expense. Despite increasingly efficacious drugs, only 20-25% of patients treated with biologic therapies achieve completely clear skin (PASI 100) and even fewer achieve this if they have experienced failures of multiple biologics.

MeSH terms

  • Biological Factors / therapeutic use
  • Biological Products* / therapeutic use
  • Humans
  • Psoriasis* / diagnosis
  • Psoriasis* / drug therapy
  • Psoriasis* / genetics
  • Severity of Illness Index
  • Transcriptome
  • Treatment Outcome
  • Ustekinumab / therapeutic use

Substances

  • Ustekinumab
  • Biological Factors
  • Biological Products